Rotate your injection spot every week
Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases
Semaglutide targets one receptor (GLP-1)
[DOI] [PubMed] [Google Scholar] Associated Data This section collects any data citations, data availability statements, or supplementary materials included in this article
Contact your GP or diabetes specialist if you experience: Persistent or severe nausea and vomiting that prevents adequate fluid or food intake, as this may lead to dehydration and acute kidney injury Signs of dehydration , including reduced urination, dark urine, dizziness, or extreme thirst Unexplained weight loss beyond what is expected or desired Symptoms of hypoglycaemia (low blood sugar), especially if taking Rybelsus alongside insulin or sulfonylureassymptoms include trembling, sweating, confusion, rapid heartbeat, and hunger A lump in the neck, hoarseness, difficulty swallowing, or shortness of breath (which should be promptly evaluated by your GP) Changes in vision or worsening of existing eye problems , particularly if you have diabetic retinopathy Seek urgent same-day medical assessment (via GP, NHS 111, or A&E) if you develop: Symptoms suggestive of acute pancreatitis : severe, persistent abdominal pain with or without vomiting, particularly if radiating to the back Biliary-type pain or jaundice (yellowing of the skin or whites of the eyes) Call 999 or attend A&E immediately if you develop: Signs of a serious allergic reaction : difficulty breathing, swelling of the face, lips, tongue, or throat, or severe skin reactions Severe symptoms with collapse or extreme distress Regular monitoring is essential for all patients on Rybelsus
